New imaging agent for lymphoma shows promise but trial stalls
NCT ID NCT06125028
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tested a new radioactive imaging agent called [68Ga]Ga-PentixaFor to see if it could better detect lymphoma tumors compared to the standard PET scan. The study aimed to enroll adults with marginal zone lymphoma who had not yet been treated. However, the trial was terminated early after only 8 participants, so the results are not conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[68Ga]Ga-PentixaFor (a radioactive imaging agent)
What this could lead to
If successful, this imaging agent could provide a more accurate way to stage certain lymphomas, potentially guiding better treatment decisions.
What could go wrong
The trial was terminated early with only 8 participants, so results are very limited. It is unclear if the agent works better than the current standard.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU La Timone
Marseille, 13005, France
-
CHU de Bordeaux
Bordeaux, 33600, France
-
CHU de Nantes
Nantes, 44093, France
-
Clinica Universidad de Navarra
Pamplona, Navarre, 31008, Spain
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, 00168, Italy
-
Hôpital Cochin
Paris, 75014, France
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, 40138, Italy
-
L'IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l
Meldola, 47014, Italy
-
Medizinische Universität Innsbruck
Innsbruck, 6020, Austria
-
Ospedale San Raffaele S.r.l.
Milan, 20132, Italy
-
Universitätsklinikum Essen
Essen, 45147, Germany
-
Universitätsklinikum Würzburg
Würzburg, 97080, Germany